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Summary
 
Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease resulting from apoptotic
destruction of 
 
b
 
 cells in the islets of Langerhans. Low expression of antioxidants and a predilection
to produce nitric oxide (NO) have been shown to underscore 
 
b
 
 cell apoptosis. With this per-
spective in mind, we questioned whether 
 
b
 
 cells could mount an induced protective response
to inflammation. Here we show that human and rat islets can be induced to rapidly express the
antiapoptotic gene A20 after interleukin (IL)-1
 
b
 
 activation. Overexpression of A20 by means
of adenovirus-mediated gene transfer protects islets from IL-1
 
b
 
 and interferon 
 
g
 
–induced apop-
tosis. The cytoprotective effect of A20 against apoptosis correlates with and is dependent on
the abrogation of cytokine-induced NO production. The inhibitory effect of A20 on cyto-
kine-stimulated NO production is due to transcriptional blockade of inducible NO synthase
(iNOS) induction; A20 inhibits the activation of the transcription factor nuclear factor 
 
k
 
B at a
level upstream of I
 
k
 
B
 
a
 
 degradation. These data demonstrate a dual antiapoptotic and antiinflam-
matory function for A20 in 
 
b
 
 cells. This qualifies A20 as part of the physiological cytoprotec-
tive response of islets. We propose that A20 may have therapeutic potential as a gene therapy
candidate to achieve successful islet transplantation and the cure of IDDM.
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T
 
ype I insulin-dependent diabetes mellitus (IDDM)
 
1
 
 is
an autoimmune disease resulting from specific destruc-
tion of the insulin-producing 
 
b
 
 cell within the islet of
Langerhans (1, 2). Many studies have focused on the initia-
tor phase of the disease, exploring the factors that permit or
provoke the autoimmune attack (2–4). More recently, greater
attention has been devoted to understanding the mecha-
nisms of 
 
b
 
 cell susceptibility to death. Although multiple
mechanisms are involved in the destruction of 
 
b
 
 cells, the
common unifying theme remains that most of these trigger
the apoptotic machinery of the 
 
b
 
 cell (5, 6).
 
b
 
 cell apoptosis can be induced by either specific T lym-
phocyte–mediated killing or proinflammatory cytokines. T
cell–mediated 
 
b
 
 cell damage occurs through direct cognate
interactions using the granzyme/perforin or Fas/Fas ligand
(FasL) systems (7, 8). Cytokine-mediated 
 
b
 
 cell apoptosis
requires the active participation of the 
 
b
 
 cells. The intraislet
release of IL-1
 
b
 
, TNF-
 
a
 
, and IFN-
 
g
 
 by activated mono-
nuclear cells activates 
 
b
 
 cells to upregulate inducible nitric
oxide synthase (iNOS) (9, 10). Generation of iNOS results
in the production of high levels of nitric oxide (NO) and, to
a lesser extent, superoxide (11, 12). NO and its reactive oxy-
gen species derivatives, including peroxynitrite (OONO
 
2
 
),
are cytotoxic to 
 
b
 
 cells (13, 14). NO-mediated toxicity is
the predominant mechanism responsible for 
 
b
 
 cell dysfunc-
tion and apoptosis induced by soluble mediators. In addi-
tion to its direct toxic potential, NO induces Fas expression
on 
 
b
 
 cells, priming them to T lymphocyte–mediated killing
(15). The central role played by NO in the pathophysiology
of 
 
b
 
 cell loss during IDDM is directly demonstrated by the
acceleration of IDDM in nonobese diabetic (NOD) mice
(a well-studied experimental model of autoimmune diabe-
tes) carrying the 
 
inos
 
 transgene under the control of the in-
sulin promoter (16).
Since the early work of Reckard et al. (17) and Ballinger
(18) showing that islet transplantation could cure diabetes
in rodents, islet transplantation for humans has been re-
garded as a potential cure for diabetes (17–20). However,
several obstacles still need to be overcome before successful
islet transplantation becomes a reality, namely, (a) primary
 
1
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nonfunction in the immediate posttransplantation period, (b)
recurrence of autoimmune disease, and (c) allograft rejection
(21–23). Whether related to hypoxia, loss of nutrients, in-
duction of nonspecific inflammatory reactions, or immune
effectors implicated in the development of autoimmune dis-
ease or allograft rejection, the final outcome of these pro-
cesses is destruction of the transplanted islets by apoptosis.
One way to achieve successful islet transplantation for the
treatment of IDDM would be to genetically engineer 
 
b
 
 cells
to express antiapoptotic and antiinflammatory proteins (24).
The zinc finger protein A20 represents one such candidate
for genetic engineering of 
 
b
 
 cells. A20 was originally de-
scribed as an antiapoptotic TNF-
 
a
 
–induced gene in endo-
thelial cells (25, 26). Besides protection from apoptosis, we
have demonstrated previously that A20 also inhibits proin-
flammatory responses in endothelial cells (27, 28). In this
paper, we evaluate the efficacy of A20 to protect islets from
apoptosis. We demonstrate that recombinant adenovirus
(rAd)-mediated gene expression of A20 in rodent islets
protects against cytokine-induced apoptosis and inhibits cyto-
kine-induced NO generation. A20 suppresses cytokine-
induced NO generation at the level of iNOS transcription
through blockade of the transcription factor, nuclear factor
 
k
 
B (NF-
 
k
 
B). Furthermore, we report for the first time that
A20 mRNA is rapidly induced in human and rat islets after
cytokine stimulation. These later data indicate that A20 is
part of the physiological protective response of islets, fur-
ther supporting its consideration for human gene therapy.
 
Materials and Methods
 
Islets.
 
Rats (male Sprague-Dawley) were purchased from
The Jackson Laboratory, and islets were isolated as described pre-
viously (23). Human islets were a gift from Dr. C. Ricordi (Dia-
betes Research Institute, University of Miami School of Medicine,
Miami, FL). Both rodent and human islets were cultured in RPMI
1640, 10% FCS with 2 mM 
 
l
 
-glutamine, 5 mM 
 
d
 
-glucose, and 50
U/ml of penicillin and streptomycin, at 37
 
8
 
C with 5% CO
 
2
 
.
 
Analysis of A20 mRNA Expression in Islets.
 
Total mRNA was
isolated from human and rodent islets (RNeasy Mini Protocol;
Qiagen), and cDNA was synthesized using random hexamers (Su-
perscript Preamplification System for First Strand cDNA Synthesis;
GIBCO BRL). PCR reactions were performed with the following
primers: rodent 
 
b
 
-actin: sense, 5
 
9
 
-CCTGACCGAGCGTGGCTA-
CAGC-3
 
9
 
, and antisense, 5
 
9
 
-AGCCTCAGGGCATCGGAAC-3
 
9
 
;
A20: sense, 5
 
9
 
-TTTGAGCAATATGCGGAAAGC-3
 
9
 
, and anti-
sense, 5
 
9
 
-AGTTGTCCCATTCGTCATTCC-3
 
9
 
; rat iNOS: sense,
5
 
9
 
-TGACCTGAAAGAGGAAAAGGAC-3
 
9
 
, and antisense,
5
 
9
 
-CCAGTTTTTGATCCTCACGTG-3
 
9
 
. The PCR reaction
was optimized for each primer pair. PCR was performed over a
range of cycles (15–40) to ensure that amplification occurred in the
linear range, and equal starting amounts of each sample were used.
 
rAd Vectors and Gene Transduction of Rodent Islets.
 
The rAd
vector expressing A20 (rAd.A20) was a gift from Dr. V. Dixit (De-
partment of Molecular Oncology, Genentech, Inc., South San Fran-
cisco, CA); the control vector expressing 
 
b
 
-galactosidase (rAd.
 
b
 
-gal)
was a gift from Dr. R. Gerard (Department of Biochemistry, Uni-
versity of Texas, Southwestern Medical Center, Dallas, TX). Islets
were infected with rAd vectors immediately after isolation as de-
scribed previously for other cell types (28). After infection, islets were
 
cultured for an additional 24 h before being used for further experi-
ments. For all experiments (unless otherwise stated), 200 islets were
cultured in 500 
 
m
 
l of media in 24-well tissue culture plates.
 
Analysis of A20 Protein Expression and Islet Viability after rAd In-
fection.
 
Expression of A20 protein after rAd.A20 gene transduc-
tion in islets was determined by Western blotting using standard
techniques. A20 protein expression was detected with a poly-
clonal A20 antiserum (A20-NT) raised against an NH
 
2
 
 terminus
peptide sequence of human A20 (IRERTPEDIFKPTN). Islet
viability after viral infection was assessed by staining with propid-
ium iodide (10 
 
m
 
g/ml) and calcein-AM (2 
 
m
 
M; Molecular
Probes), then determined by two-color fluorescence microscopy.
 
Flow Cytometric Analysis of Apoptosis.
 
Islet cultures were stim-
ulated with recombinant murine IL-1
 
b
 
 (10 U/ml) and recombi-
nant rat IFN-
 
g
 
 (300 U/ml) (R&D Systems) for 40 h. Islets were
then harvested, dispersed, fixed in 70% ethanol, and suspended
into DNA staining buffer (PBS, pH 7.4, containing 0.1% Triton
X-100, 0.1 mM EDTA, 50 
 
m
 
g/ml propidium iodide, 50 
 
m
 
g/ml
RNase A). Islet DNA content was analyzed on a FACScan™ us-
ing CELLQuest™ acquisition software (Becton Dickson Immu-
nocytometry Systems). Islets with a normal DNA content (
 
$
 
2 N)
were scored as viable, whereas islets with a hypodiploid DNA
content (
 
,
 
2 N, termed A
 
8
 
) were scored as apoptotic. To exclude
debris and apoptotic cell-free fragments, all events with an FL-2
area profile below that of chicken erythrocyte nuclei were ex-
cluded from analysis.
 
Determination of iNOS Protein Expression.
 
To determine the
effects of A20 expression on iNOS protein induction, islets were
stimulated with IL-1
 
b
 
 (10 U/ml) for 24 h. iNOS protein expres-
sion was determined by Western blotting using the polyclonal
anti-iNOS Ab, N-20 (Santa Cruz).
 
Determination of NO (Nitrite) Generation.
 
Culture media were
analyzed for NO levels (measured as nitrite) by adding 50 
 
m
 
l of
Griess reagent (equal volume of 1% sulfanilamide in 0.1 M HCl
and 0.1% 
 
N
 
-[-1-naphthyl-ethylenediamine dihydrochloride]) to
50 
 
m
 
l of culture media. Nitrite concentration was determined by
spectrophotometry (560 nM) from a standard curve (0–200 
 
m
 
M)
derived from NaNO
 
2
 
. NO data are expressed as mean 
 
6 
 
SD
[nitrite] in 
 
m
 
M per 200 islets.
 
Analysis of the Role of NO in Cytokine-induced Apoptosis.
 
To
examine whether NO could directly induce apoptosis, islets were
treated for 24 h with the NO donors 
 
S
 
-nitrosoglutathione
(GSNO) or 
 
N
 
-(2-aminoethyl)-
 
N
 
-(2-hydroxy-2-nitrosohydrazino-
1,2-ethylenediamine (NONOate) over a range of concentrations
(0.001–10 mM). To determine the role of NO in cytokine-
induced apoptosis, islets were treated with IL-1
 
b
 
 (10 U/ml) and
IFN-
 
g
 
 (300 U/ml) in the presence or absence of the NOS inhib-
itor 
 
l
 
-
 
N
 
5
 
-(1-iminoethyl) ornithine, dihydrochloride (L-NIO)
used at the optimal concentration of 500 
 
m
 
M. The extent of islet
apoptosis and NO generation was determined as described above.
Transient Transfection of the Murine b Cell Line, b-TC3. b-TC3
cells (29) were plated at a density of 1.5 3 106 cells/well into
6-well tissue culture plates and transfected 24 h later using the
Lipofectamine-Plus reagent (GIBCO BRL) with 1 mg total DNA.
Specifically,  b-TC3 cells were transfected with 0.6 mg of the
iNOS reporter (pGLH/H2; containing 1,755 bp of the murine
iNOS promoter linked to a luciferase gene [30]), a gift of Dr.
W.J. Murphy (Wilkinson Laboratory of the Kansas Cancer In-
stitute, University of Kansas Medical Center, Kansas City, KS);
0.3 mg of an expression plasmid containing the human A20 gene
(pcDNA3/HA-A20) or the control empty plasmid pcDNA3; and
0.1 mg of a b-gal reporter (driven by the CMV promoter), used
to correct for transfection efficiency. 24 h after transfection, cells1137 Grey et al.
were stimulated with IL-1b (100 U/ml) for 36 h. These condi-
tions were shown to be optimal in preliminary experiments (data not
shown). Luciferase and b-gal activity were assessed as described
(27). Data are expressed as relative luciferase activity according to
the formula: luciferase light units/b-gal light units 3 100.
Electrophoretic Mobility Shift Assay. To determine the effect of
A20 overexpression on the transcription factor NF-kB, islets
(1,000 islets/1 ml media in 24-well tissue culture plates) were
stimulated with IL-1b (100 U) for 1 h. Islet nuclei were recov-
ered by an isoosmotic/NP-40 lysis procedure, and nuclear pro-
teins were extracted as described (31). DNA binding reactions were
performed by incubating 5 mg of nuclear proteins with 1 mg of
poly(dI-dC) and 105 cpm of radiolabeled NF-kB consensus oli-
gonucleotide, 59-AGT TGA GGG GAC TTT CCC AGG C-39
(Promega Corp.). For competition assays, 1.75 pmol of either
unlabeled NF-kB or an unrelated oligonucleotide was added to
the reaction mixture. Supershift analysis was conducted by adding
0.1 mg of Ab specific for p50/NF-kB1, p65/RelA, Rel-B, c-Rel, or
Ets-1 (Santa Cruz) to the reaction 1 h before the addition of radiola-
beled oligonucleotide. The DNA binding reactions were resolved
on a 6% polyacrylamide gel and analyzed by autoradiography.
Determination of IkBa Degradation. The effect of A20 expres-
sion on IkBa protein degradation was determined by Western blot
analysis, after treatment with IL-1b (100 U/ml) for 0, 15, and 60
min. IkBa protein expression was detected using the polyclonal
anti-IkBa Ab, C-20 (Santa Cruz).
Statistical Analysis. All statistical analysis was conducted using
the alternate Welch’s method.
Results
A20 Is Induced in Islets of Langerhans in Response to Inflam-
matory Stimuli. We first examined if A20 was expressed
constitutively in islets and whether A20 expression could be
induced by cytokine stimulation. No or weak constitutive
A20 mRNA was detected in rat and human islets as analyzed
by reverse transcription (RT)-PCR (Fig. 1, a and b). A20
mRNA was rapidly induced (within 1–2 h) in both rat and
human islets after IL-1b stimulation (Fig. 1, a and b). Rat b
insulinoma cells (Rin5F) could also be induced to rapidly
express A20 mRNA after IL-1b stimulation, indicating
that  b cells specifically express A20 (Fig. 1 c). The identity
of the A20 PCR product was confirmed by sequence anal-
ysis (data not shown). Our data demonstrate that A20 is an
early response gene in cytokine-activated islets.
rAd-mediated Gene Transfer of A20 to Rat Islets of Langerhans
Achieves High Level of Expression without Toxic Effects. To
study the function of A20 in islets, we overexpressed A20
by rAd-mediated gene transfer. Islets infected with a recom-
binant b-gal adenovirus (rAd.b-gal) were used as controls.
Islets infected in vitro with a rAd carrying the A20 trans-
gene (rAd.A20) expressed high levels of A20 protein (Fig.
2 a). In vitro–infected islets showed normal morphology
and viability in culture (Fig. 2 b). Infection with greater
multiplicity (MOI; e.g., $30:1) led to significant toxicity
in our system (data not shown) and hence MOIs in the range
of 1–20:1 were used.
To test the function of islets after infection with rAd, 500
freshly isolated islets were infected in vitro with rAd.b-gal
(MOI 10:1) for 1 h at 378C. Islets were then washed and
transplanted under the kidney capsule of B6AF1 mice ren-
dered diabetic by intraperitoneal injection of streptozotocin
(160 mg/kg) 7–14 d before the day of transplantation (32).
All transplanted animals were normoglycemic (glucose levels
76–116 mg/dl) by day 4–5 after transplantation. This result
Figure 1. A20 mRNA is induced in human and rat islets after stimulation
with IL-1b. After isolation, 500–1,000 islets were cultured overnight and
then stimulated with IL-1b (100 U/ml). A20 mRNA expression was deter-
mined by RT-PCR in (a) human islets, 1 h after stimulation; (b) rat islets,
2 h after stimulation; and (c) rat insulinoma cells (Rin5F), 1 and 2 h after
stimulation. A20 mRNA was rapidly induced after IL-1b activation in both
species. media, no IL-1b stimulation; TC, template control without cDNA.
Figure 2. rAd–mediated gene transfer induces high A20 expression in
rat islets without toxic effects. (a) To determine the level of A20 expres-
sion after gene transduction, rat islets infected with rAd.A20 (MOI 1:1,
10:1, and 20:1) were cultured for 24 h and assessed for expression of A20
protein by Western blotting with the polyclonal Ab, A20-NT. Controls
were noninfected islets (1.) and rAd.b-gal–infected islets (2.). (b) Non-
infected islets (NI) and rAd.A20 (MOI 10:1 and 20:1)–infected islets
were cultured for 48 h and assessed for cell viability by staining with cal-
cein-AM (2 mM) and propidium iodide (10 mg/ml). Viable cells stain
green, whereas necrotic and apoptotic cells label red. Islets infected with
rAd.A20 express high levels of the transgene and show normal morphol-
ogy with the absence of central necrosis.1138 Cryoprotective Function of A20 in Islets
indicates that adenoviral infection of islets per se does not
alter their function.
A20 Overexpression Protects Islets from Cytokine-induced Apop-
tosis. Previous work has demonstrated that A20 is an early
response gene that protects cells against cytokine-mediated
cytotoxicity (25, 26). The proinflammatory cytokine IL-1b
is cytotoxic to b cells and represents a significant mediator
of b cell apoptosis in IDDM, especially in combination with
IFN-g (10). Therefore, we examined whether A20 would
protect islets against IL-1b– and IFN-g–mediated toxicity.
IL-1b and IFN-g used at the optimal dose of 10 and 300
U/ml, respectively, induced a significant percentage of apop-
tosis in rat islets after 40 h in culture (Fig. 3). This percent-
age (mean 6 SD, n 5 4 independent experiments) reached
57.58 6 16.51 and 55.08 6 18.35% in both noninfected
and control rAd.b-gal–infected islets, respectively (P , 0.01,
n 5 4), as evaluated by FACS® analysis of DNA content
(Fig. 3). In contrast, rAd.A20-infected islets were protected
from IL-1b– and IFN-g–mediated apoptosis; the percent-
age of apoptosis in these islets was not significantly different
(P 5 0.714, n 5 4) from that observed in non–cytokine-
activated control islets (Fig. 3). These data demonstrate that
A20 protects islets from cytokine-mediated apoptosis.
A20-mediated Protection from Apoptosis Correlates with Sup-
pression of NO Production. There is substantial evidence that
free radical generation, such as release of NO and peroxy-
nitrites, mediates the proapoptotic effects of cytokines on
islets (9, 13, 14). Therefore, we examined the levels of NO
released in the culture medium of noninfected, rAd.b-gal–,
and rAd.A20-infected islets 40 h after cytokine stimulation.
Noninfected and rAd.b-gal–infected islets produced equally
high levels of NO after stimulation with IL-1b and IFN-g
(Fig. 4). In contrast, NO production in rAd.A20-infected
islets was totally suppressed (P , 0.0001, n 5 4) compared
with noninfected and rAd.b-gal–infected islets and was not
significantly different (P 5 0.099, n 5 4) from background
levels observed in non–cytokine-activated groups (Fig. 4).
Thus, the percentage of islets undergoing apoptosis for
each treatment correlated with their production of NO.
IL-1b– and IFN-g–induced Apoptosis Is Mediated by NO.
Our data demonstrate that A20 can protect islets from cyto-
kine-induced apoptosis. Furthermore, they show that the
antiapoptotic effect of A20 correlates with suppression of
cytokine-induced NO production, suggesting that A20 is
protecting islets through effects on NO generation. This
hypothesis is in accordance with data from the literature
showing that NO is a key mediator of cytokine-induced is-
let cytotoxicity (9, 14, 33). To determine whether the anti-
apoptotic effect of A20 was a direct result of its ability to
suppress NO production, we examined the role of NO in
cytokine-induced apoptosis of islets. We first examined if
NO could directly induce apoptosis in rat islets. Rat islets
were cocultured with one of two NO donors, NONOate
or GSNO, at various concentrations ranging from 0.01 mM
to 10 mM. 16 h later, islets were examined for induction of
apoptosis (Fig. 5 a). Both NONOate and GSNO, in a dose-
dependent manner, induced significant levels of apoptosis
in rat islets. However, NONOate was 10-fold more potent
than GSNO due to its higher release of NO in the medium
(Fig. 5 a, and data not shown). Given that NO is able to di-
rectly induce apoptosis in rat islets, we next examined
whether NO was the agent responsible for islet apoptosis
after cytokine stimulation. The NOS inhibitor L-NIO (500
mM) was added to cytokine-stimulated islets. Islets stimu-
Figure 3. A20 protects rat islets against cytokine-induced apoptosis.
Noninfected (NI), rAd.b-gal–, and rAd.A20-infected islets were cultured
in the presence or absence of IL-1b (10 U/ml) and IFN-g (300 U/ml) for
40 h, and the percentage of apoptotic cells was determined by flow cy-
tometry. The percentage of apoptosis in each treatment (given in upper
right corner) was calculated by analysis of the percentage of events in the
subdiploid region (termed A°; where DNA content ,2 N) from the FL-2
area histogram (total of 10,000 events collected). The data presented are
representative of four independent experiments conducted. Results dem-
onstrate that expression of A20 in islets protects them from cytokine-
mediated apoptosis.
Figure 4. A20 inhibits production of NO by cytokine-activated rat is-
lets. Noninfected (NI), rAd.b-gal–, and rAd.A20-infected islets were cul-
tured in the presence or absence of IL-1b (10 U/ml) and IFN-g (300 U/ml)
for 40 h, and NO levels were determined in the culture medium. There
was no significant difference in IL-1b–stimulated NO production by
rAd.b-gal–infected islets compared with noninfected islets (P 5 0.315).
However, NO production was totally abrogated in A20-expressing islets
compared with noninfected or rAd.b-gal–infected islets (P , 0.0001).
Nitrite levels (mM/200 islets) are the mean 6 SD of triplicate determina-
tions, pooled from four independent experiments.1139 Grey et al.
lated with IL-1b and IFN-g underwent apoptosis and gen-
erated high levels of NO (Fig. 5 b). In contrast, islets stim-
ulated with IL-1b and IFN-g in the presence of L-NIO were
completely protected from apoptosis (P , 0.001, n 5 3), and
NO generation was suppressed to below background levels
(P , 0.01, n 5 3; Fig. 5 b). Taken together, these data
demonstrate that NO is the central mediator of cytokine-
induced islet apoptosis.
A20 Inhibits Cytokine-induced iNOS Upregulation in Islets
through Inhibition of inos Gene Transcription. To clarify the
mechanism(s) by which A20 was suppressing NO produc-
tion, we examined the effects of A20 overexpression on
iNOS protein expression, steady state mRNA levels, and
regulation of gene transcription. For these and subsequent
experiments, islets were stimulated with IL-1b alone, as
IFN-g by itself had little or no effect on NO induction
(data not shown).
We examined whether A20 overexpression would mod-
ulate the induction of iNOS protein after cytokine stimula-
tion. Noninfected and rAd.b-gal–infected islets expressed
high levels of iNOS protein 24 h after activation with IL-1b
(Fig. 6 a). These data are in accordance with previous stud-
ies demonstrating that in islets, cytokine treatment results in
de novo production of iNOS mRNA and protein (34). In
contrast, IL-1b–mediated upregulation of iNOS protein
was totally suppressed in A20-expressing islets (Fig. 6 a).
Accordingly, NO generation after IL-1b stimulation was
highly suppressed ($90%) in A20-expressing islets com-
pared with the significant NO levels detected in nonin-
fected and rAd.b-gal infected islets (data not shown).
To determine the underlying mechanism by which A20
was suppressing iNOS protein upregulation, we examined,
by RT-PCR analysis, iNOS steady state mRNA levels after
IL-1b activation. No iNOS mRNA was detected in non-
stimulated islets, whereas iNOS transcript was induced 5 h
after IL-1b stimulation in both noninfected and rAd.b-gal–
infected islets (Fig. 6 b). In contrast, no iNOS mRNA was
detected in rAd.A20-infected islets (Fig. 6 b).
It has been established that induction of iNOS mRNA
expression by IL-1b is regulated at the transcription level
(30, 34, 35). Therefore, we questioned whether the inhibi-
tory effect of A20 on inos gene upregulation occurred at
the level of gene transcription. To address this possibility,
b-TC3 cells were cotransfected with a murine iNOS re-
porter (30) and a human A20 expression plasmid or the
control plasmid, pcDNA3. b-TC3 cells were stimulated with
IL-1b (100 U/ml) for 36 h after transfection, and luciferase
values were calculated as described in Materials and Meth-
ods. As shown in Fig. 6 c, IL-1b stimulation resulted in a
significant two- to threefold induction of the iNOS re-
porter in the pcDNA3-transfected b-TC3 cells (mean fold
induction 6 SD, 2.23 6 0.747; P , 0.0001, n 5 5). In
contrast, IL-1b induction of the iNOS reporter in A20-
expressing b-TC3 cells was totally suppressed (P , 0.0001,
n 5 5) to the extent that there was no difference relative to
background levels in pcDNA3-transfected b-TC3 cells (P 5
0.75, n 5 5). Interestingly, A20 overexpression also signifi-
cantly reduced the basal (nonstimulated) iNOS reporter ac-
tivity by z50% (P , 0.005, n 5 5) compared with b-TC3
cells transfected with pcDNA3.
A20 Inhibits NF-kB Activation at a Level Upstream of IkBa
Degradation. Our data indicate that A20 can suppress the
IL-1b–dependent activation of the inos gene. Previous re-
ports have implicated the transcription factor NF-kB as an
essential component of this activation (34, 36). Therefore,
we examined whether A20 was suppressing inos transcription
via modulation of NF-kB activation. To check whether
A20 expression was altering NF-kB translocation to the
nucleus, we performed electrophoretic mobility shift assays
(EMSAs) using nuclear extracts isolated from noninfected,
rAd.b-gal–, and rAd.A20-infected islets after IL-1b stimu-
Figure 5. NO mediates islet apoptosis induced by IL-1b and IFN-g. (a)
NO donors induce apoptosis in rat islets. Islets were left untreated or
were stimulated with GSNO (1.0 mM) or NONOate (0.1 mM) for 16 h,
and the percentage of apoptotic cells was determined by flow cytometry.
The percentage of apoptotic events was calculated as described and is
given in the upper right corner. Data are from a representative experi-
ment of three independent experiments conducted. (b) The l-arginine
analogue L-NIO inhibits both apoptosis and NO generation in rat islets.
Islets were cultured in the presence or absence of IL-1b (10 U/ml) and
IFN-g (300 U/ml) for 40 h with or without L-NIO (2.2 mM), and the
percentage of apoptosis for each condition was measured by flow cytome-
try. Data from three independent experiments were pooled and are given
as the percentage of apoptosis (mean 6 SD). NO production (mean 6
SD, [nitrite] mM) was measured in the culture medium from each condi-
tion and is given in the chart. Suppression of NO production correlated
with protection from apoptosis.1140 Cryoprotective Function of A20 in Islets
lation (Fig. 7 a). A slow migrating complex, binding to an
NF-kB consensus sequence, was observed in noninfected
and rAd.b-gal–infected islets 1 h after stimulation with IL-1b
(Fig. 7 a, arrow). In contrast, this complex was not detected
in nuclear extracts from rAd.A20-infected islets after IL-1b
stimulation. This complex was resolved by supershift analy-
sis to comprise the p50 and p65 NF-kB subunits (Fig. 7 b).
The fastest migrating band was not affected by any treat-
ment and most likely represents a nonspecific protein in-
teraction. These data show that A20 inhibits, in islets, the
translocation of NF-kB to the nucleus.
Degradation of the natural inhibitor of NF-kB, IkBa, in
response to IL-1b is a prerequisite for NF-kB translocation
(37, 38). We next examined whether expression of A20 in
islets was affecting the degradation of IkBa in response to
IL-1b. Western blot analysis of cytoplasmic extracts from
noninfected and rAd.b-gal–infected islets showed that IkBa
was rapidly degraded within 15 min after IL-1b stimulation
(Fig. 7 c). In contrast, expression of A20 in islets totally inhib-
ited the degradation of IkBa observed after IL-1b stimulation
(Fig. 7 c). To ascertain that expression of A20 in islets was not
simply delaying IkBa degradation, we examined IkBa levels
at several time points after IL-1b stimulation (e.g., 20, 30, 45,
and 60 min). No IkBa degradation was observed at any of
these time points (Fig. 7 c, and data not shown).
Discussion
IDDM is an autoimmune disease characterized by the
specific destruction of b cells in islets of Langerhans (3).
Cumulative evidence suggests that apoptosis of the b cell is
a critical component of IDDM at both the initiation and
effector phases of the disease (5). Transplantation of islets of
Langerhans represents a potential cure for IDDM, but here
again the success of this treatment is hampered by destruc-
tion of the islets and loss of b cells to apoptosis (23). b cell
apoptosis can be triggered by both nonspecific inflamma-
tory reactions and specific immune responses (3, 21). One
potential solution to overcome the susceptibility of b cells
to apoptosis is the use of gene therapy to express genes that
may impart protective properties on islets, thus enabling
successful transplantation (24, 39).
Little is currently known about the expression of cyto-
protective genes in b cells and the molecular basis of their
susceptibility to apoptosis. Recent reports demonstrated
that islets constitutively express the prototypic antiapoptotic
molecule Bcl-2, the stress-related heat-shock protein HSP70,
and several free radical scavenging enzymes such as manga-
nese superoxide dismutase (MnSOD) and catalase (40). De-
spite expression of these proteins, b cells remain particu-
larly sensitive to apoptosis when challenged with additional
cellular stress (41). This is in part explained by their lower
expression of constitutive cytoprotective genes (41). With
this perspective in mind, we questioned whether islets are
able to mount a protective response to inflammation. In
this report, we examined whether b cells could be induced
to express the antiapoptotic protein A20. A20 was origi-
nally described as a TNF-a–inducible 7-Zn finger protein
in endothelial cells (25). Its expression can also be induced
in response to a variety of inflammatory stimuli, such as
Figure 6. A20 inhibits de novo induction of inos, an NF-kB–dependent gene in rat islets. (a) In-
duction of iNOS protein in A20-expressing islets. Noninfected (NI), rAd.b-gal–, and rAd.A20-
infected islets were cultured in the presence or absence of IL-1b (10 U/ml) for 24 h, and iNOS
protein levels were assessed by Western blot analysis. The 130-kD iNOS protein was revealed using
the polyclonal Ab, N-20, and its presence is indicated by the arrow. iNOS protein was not detected
in A20-expressing islets after IL-1b stimulation. Data are from a representative experiment of three
independent experiments conducted. (b) Induction of iNOS steady state mRNA levels in A20-
expressing islets. rAd.b-gal– and rAd.A20-infected islets were cultured in the presence or absence of
IL-1b (100 U/ml) for 6 h, and both iNOS and b-actin steady state mRNA levels were analyzed by RT-PCR. Upregulation of iNOS mRNA was sup-
pressed in A20-expressing islets. TC, template control. (c) Induction of an iNOS reporter in A20-expressing islets. b-TC3 cells were transiently cotrans-
fected with a luciferase reporter construct containing the iNOS promoter and a human A20 expression plasmid (A20). Control cells were transfected with the
iNOS reporter and the control construct pcDNA3 (pcDNA3). 24 h later, b-TC3 cells were stimulated with IL-1b (100 U/ml) for 36 h, and relative luciferase
activity (normalized to b-gal light units) was determined as described in Materials and Methods. A20 inhibited IL-1b–induced activation of the iNOS re-
porter (P , 0.0001). Data (expressed as relative luciferase activity [mean 6 SEM]) are representative of five independent experiments conducted in triplicate.1141 Grey et al.
LPS, CD40 ligation, the LMP1 protein of EBV, and the
Tax protein of HIV (42–45). The rapid induction of A20
mRNA by these diverse stimuli requires the activation of
the transcription factor NF-kB. Two kB binding elements
map within the A20 promoter and are essential for its ex-
pression (46). Here we show that expression of A20 is rap-
idly induced in b cells in response to IL-1b. This is the first
report showing the induced expression of the antiapoptotic
gene A20 in b cells. Further, our data show that IL-1b in-
duces the activation of NF-kB in islets, which concurs with
its ability to upregulate the expression of A20. The rapid
kinetics of A20 expression in islets suggests that, as in en-
dothelial cells, it may be a component of their physiological
protective response to injury (47).
Having established that A20 is a rapid response gene in b
cells, we examined whether A20 maintained its antiapop-
totic function in islets. Expression of A20 in islets by means
of an rAd protects them from apoptosis induced by IL-1b
and IFN-g. The protective effect of A20 against IL-1b–
and IFN-g–induced apoptosis is critical given the central role
of IL-1b in b cell dysfunction and destruction during IDDM
(9, 48). IL-1b inhibits glucose-dependent insulin secretion,
impairs glucokinase synthesis, and induces cell death by apop-
tosis (49, 50). Inhibition of IL-1b using neutralizing mAbs
prevents diabetes progression in NOD mice (51). The path-
way by which IL-1b mediates b cell destruction and toxicity
has recently been clarified. IL-1b is produced by activated
resident macrophages within the islets (48, 21, 52, 53). Once
produced, IL-1b acts directly and selectively upon b cells
to induce iNOS, leading to the production of high and sus-
tained levels of NO and to a lesser extent superoxide (12,
54). NO directly induces apoptosis of b cells and is the me-
diator of the multiple toxic effects of IL-1b on b cells (55–57).
We confirmed the apoptotic potential of NO in our system
with the NO donors GSNO and NONOate, which rap-
idly induced apoptosis of rat islets. Furthermore, the addi-
tion of the NOS inhibitor L-NIO to cytokine-activated
islets prevented both NO production and apoptosis. These
data demonstrate that endogenously generated NO is the
mediator of cytokine-induced islet apoptosis in our system.
The central role of NO in cytokine-mediated b cell tox-
icity prompted us to examine whether the protective effect
of A20 in islets was associated with modulation of NO lev-
els. We found that expression of A20 in islets abrogated
NO production in response to cytokines. Taken together
with our data showing that pharmacologic suppression of
NO production also protects from cytokine-induced apop-
tosis, these data establish the suppression of NO production
as one mechanism by which A20 protects islets (58). The
suppression of NO production by A20 could also impact
on T cell–dependent b cell destruction. Indeed, NO facili-
tates T cell–dependent killing via upregulation of Fas on
human islets (15, 59). Ongoing work in our laboratory is
aiming at determining whether expression of A20 in islets
will also protect b cells against T cell–mediated cytotoxic-
ity via the perforin/granzyme or the Fas/FasL pathway.
The mechanism by which A20 suppresses cytokine-
induced NO production is shown to be via inhibition of
IL-1b–induced iNOS mRNA and protein expression. Ex-
pression of iNOS protein in islets is regulated by de novo
transcription of the inos gene (30, 34, 35). We reasoned that
the absence of iNOS protein and mRNA after cytokine
Figure 7. A20 inhibits NF-kB activation in
rat islets, at a level upstream of IkBa degrada-
tion. (a) NF-kB activation in A20-expressing
islets. Noninfected (NI), rAd.b-gal–, and
rAd.A20-infected islets were cultured in the
presence or absence of IL-1b (100 U/ml)
for 1 h, and the presence of nuclear binding
proteins for an NF-kB consensus sequence
was determined by EMSA. A slow migrating
complex binding to an NF-kB oligonucleo-
tide was detected in nuclear extracts from
noninfected and rAd.b-gal–infected islets
after IL-1b treatment (arrow). No complex
was observed in A20-expressing islets after
IL-1b stimulation. (b) Supershift analysis of
nuclear extracts from noninfected islets stim-
ulated with IL-1b (100 U/ml) for 1 h was
performed to determine the identity of the
NF-kB complex. Nuclear extracts were in-
cubated with 0.1 mg of polyclonal Ab di-
rected against p50, p65/RelA, Rel-B, c-Rel,
or Ets-1. Small arrows indicate supershifted
complexes. The induced NF-kB binding
complex comprised p50 and p65 subunits.
(c) IkBa degradation in A20-expressing is-
lets. Noninfected, rAd.b-gal–, and rAd.A20-
infected islets were stimulated with IL-1b
(100 U/ml) for the indicated times, and
IkBa degradation in the cytoplasm was as-
sessed by Western blot analysis. IL-1b in-
duced a rapid transient decrease in IkBa protein levels in noninfected and rAd.b-gal–infected islets, whereas no degradation of IkBa was observed in
A20-expressing islets. The data shown are from a representative experiment of three independent experiments performed.1142 Cryoprotective Function of A20 in Islets
stimulation points to a blockade at the level of transcrip-
tion. Indeed, we found that A20 suppresses IL-1b–induced
activation of a murine iNOS reporter, indicating that A20
was regulating iNOS expression at the level of gene tran-
scription. Since NF-kB is the major transcription factor re-
sponsible for de novo activation of inos transcription by in-
flammatory stimuli including IL-1b, we examined the effect
of A20 overexpression on NF-kB activation (60). We found
that A20 suppresses the activation of the transcription factor
NF-kB in islets. Expression of other NF-kB–dependent pro-
inflammatory genes involved in IDDM, such as intercellu-
lar adhesion molecule 1 (ICAM-1), are also expected to be
blunted by A20, thereby adding to the beneficial effect of
A20 as a gene therapy tool (61, 62). We have previously
shown that A20 has a dual antiapoptotic and antiinflamma-
tory function in primary endothelial cells (28). This dual
function is clearly maintained in islets, suggesting that inhi-
bition of NF-kB activation by A20 is an important compo-
nent of the natural physiological role of A20. The effect of
A20 seems specific to NF-kB and is not a result of a toxic
effect of A20 on the transcription machinery. Indeed, A20
overexpression had no effect on IFN-g–mediated MHC
class I upregulation (data not shown), a process requiring the
activation of the transcription factors signal transducer and
activator of transcription 1a (STAT-1a) and IFN regulatory
factor 1 (IRF-1) (63, 64).
NF-kB is a ubiquitous transcription factor constitutively
expressed in the cytoplasm in an inactive form associated to
an inhibitory protein termed IkBa (37, 38). Cellular acti-
vation by inflammatory stimuli such as IL-1b results in the
phosphorylation and subsequent degradation of IkBa, thus
allowing NF-kB to translocate into the nucleus and acti-
vate target genes such as inos (37, 38). Therefore, we exam-
ined what effect A20 had on IkBa degradation. Our data
demonstrate that A20 interferes with NF-kB activation at
a level upstream of the kinase cascade leading to IkBa
degradation, as no IkBa degradation was observed in A20-
expressing islets after IL-1b stimulation. Several potential
targets for A20 within the IL-1b–stimulated cascade lead-
ing to NF-kB activation have been reported. Yeast double
hybrid studies have demonstrated that A20 interacts with
TNF receptor–associated factor (TRAF)-1/2, TRAF-6, and
the adapter proteins 14-3-3 (65, 66, 66a). The interaction
of A20 with 14-3-3 proteins is interesting given the poten-
tial involvement of 14-3-3 (via their interaction with c-raf)
in multiple signaling cascades leading to NF-kB activation
(67). In addition, IL-1b–mediated activation of NF-kB re-
quires TRAF-6 and the IL-1 receptor–associated kinase
IRAK (68–70). Therefore, TRAF-6 is also a likely point
where A20 intercepts the IL-1b signaling cascade. Inter-
actions between A20 and TRAF-6 or 14-3-3 in islets are
currently being studied in our laboratory.
In addition, data in the literature show that IL-1b–induced
NF-kB activation and inos mRNA induction can be sup-
pressed in islets by antioxidants such as pyrrolidine dithio-
carbamate (PDTC) (34). Moreover, NF-kB is a redox-
sensitive transcription factor, as indicated by the fact that
NF-kB activation can be induced by H2O2 or, conversely,
NF-kB nuclear translocation is blocked by antioxidants such
as PDTC (71, 72). The potential for A20 to interfere at the
oxidative step in NF-kB activation is currently being tested.
Interestingly, several studies have addressed the protective
potential of antioxidants in islets by overexpressing free radi-
cal scavenging enzymes (41, 73–75). The overexpression of
MnSOD in an engineered b cell resulted in selective pro-
tection from IL-1b–induced cytotoxicity as well as a reduc-
tion in cytokine-induced NO generation (75). In addition,
transgenic expression of the antioxidant thioredoxin in b cells
of NOD mice reduced the incidence of spontaneous diabe-
tes and protected from streptozotocin-induced diabetes (76).
Interestingly, thioredoxin has been shown to inhibit NF-kB
by interfering with a redox-sensitive step required for its
activation (77, 78). Thus, in the model of Hotta et al. (76),
the protective effect of thioredoxin may involve inhibition
of NF-kB activation, given the role of NF-kB activation in
NO generation and islet destruction (36, 54, 79). Together,
these data illustrate a novel concept whereby protection of
the target (in this case, b cells) would offer a potent thera-
peutic strategy to inhibit disease occurrence even in the
presence of the effector mechanisms (cellular and soluble
mediators). This approach might constitute an alternative
to systemic modulation of the immune system as currently
practiced using diverse immunosuppressants, such as costim-
ulation blockade (80–83). Along with this approach, other
antiapoptotic genes such as bcl-2 have been proposed as
gene therapy tools to protect islets from cytokine-mediated
apoptosis. Expression of Bcl-2 in a murine b cell line did
provide modest protection from cytokine-mediated apop-
tosis (84, 85). Interestingly, bcl genes have, like A20, antiin-
flammatory properties through blockade of transcription
factors, such as NF-kB in endothelial cells (86–88). We are
currently testing whether they maintain this dual function
in islets and could synergize with A20 to protect b cells.
However, in contrast to A20, Bcl-2 is expressed constitu-
tively in islets and is not induced upon cytokine activation
(data not shown). We propose that constitutively expressed
antiapoptotic proteins such as Bcl-2 may function to pro-
tect cells from baseline cellular stress, whereas induced cyto-
protective proteins such as A20 protect cells from greater
stress caused by inflammatory reactions (47). We suggest that
A20 could be a more relevant gene therapy candidate for
protection of b cells against the additional stress encoun-
tered in the setting of transplantation and autoimmunity.
Future experiments will determine the efficacy of A20 in
both islet transplant and autoimmune diabetes models.
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